BUZZ-HK-listed Metis TechBio climbs on Boulevard Bio tie-up

** Metis TechBio 7666.HK climbs 4.7% to HK$15.28

** The firm, which develops AI-driven nanomaterial platform technologies, said it entered into a global exclusive license agreement with Deerfield Management-backed US biotechnology firm Boulevard Bio Inc

** The deal grants the US firm the global rights to develop, manufacture, commercialise Metis' experimental biologic drug MTS-128

** Metis TechBio will receive an upfront payment of $20 mln, and is eligible to receive up to $1.6 bln in development, regulatory, commercial milestone payments, plus tiered sales royalties based on product sales - co

** Since debut on May 13, Metis TechBio stock up 44.6% from the offer price of HK$10.50 apiece

** YTD, Hang Seng Biotech Index .HSBIO down 11.1%




This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.